UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 137

Sortiert nach

Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial

Journal of the American Academy of Dermatology, 2020-06, Vol.82 (6), p.1314-1320

2020

Link zum Volltext

Verfügbarkeit prüfen

A review of phototherapy protocols for psoriasis treatment

Journal of the American Academy of Dermatology, 2011-05, Vol.64 (5), p.936-949

2011

Link zum Volltext

Verfügbarkeit prüfen

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

Journal of the American Academy of Dermatology, 2014-01, Vol.70 (1), p.168-177

2014

Link zum Volltext

Verfügbarkeit prüfen

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

The Journal of dermatological treatment, 2024-12, Vol.35 (1), p.2287401-2287401

2024

Link zum Volltext

Verfügbarkeit prüfen

Treatment strategies, management of comorbidities, and the role of IL-23 inhibitors in moderate to severe psoriasis

The American journal of managed care, 2021-06, Vol.27 (10 Suppl), p.S203-S208

Bagel, Jerry

2021

Link zum Volltext

Verfügbarkeit prüfen

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis

Dermatology and therapy, 2020-12, Vol.10 (6), p.1383-1396

2020

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

The Journal of dermatological treatment, 2022-05, Vol.33 (4), p.2317-2324

2022

Link zum Volltext

Verfügbarkeit prüfen

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Journal of the American Academy of Dermatology, 2012-07, Vol.67 (1), p.86-92

2012

Link zum Volltext

Verfügbarkeit prüfen

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

Dermatology and therapy, 2018-12, Vol.8 (4), p.571-579

2018

Link zum Volltext

Verfügbarkeit prüfen

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

The Journal of dermatological treatment, 2022-05, Vol.33 (4), p.2085-2093

2022

Link zum Volltext

Verfügbarkeit prüfen

Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists

American journal of clinical dermatology, 2018-12, Vol.19 (6), p.839-852

2018

Link zum Volltext

Verfügbarkeit prüfen

Treat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy

Journal of drugs in dermatology, 2018-08, Vol.17 (8), p.918

Bagel, Jerry

2018

Link zum Volltext

Verfügbarkeit prüfen

Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab

Journal of drugs in dermatology, 2022-03, Vol.21 (3), p.235

2022

Link zum Volltext

Verfügbarkeit prüfen

Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation

Journal of the American Academy of Dermatology, 2009-01, Vol.60 (1), p.120-124

2009

Link zum Volltext

Verfügbarkeit prüfen

34313 Improvement in disease severity and quality of life in patients with atopic dermatitis (AD) treated with dupilumab for up to 18 months: Real-world evidence from the PROSE registry

Journal of the American Academy of Dermatology, 2022-09, Vol.87 (3), p.AB68-AB68

2022

Link zum Volltext

Verfügbarkeit prüfen

From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis

Journal of the American Academy of Dermatology, 2008, Vol.58 (1), p.94-105

2008

Link zum Volltext

Verfügbarkeit prüfen

Decision points for the initiation of systemic treatment for psoriasis

Journal of the American Academy of Dermatology, 2005-07, Vol.53 (1), p.101-107

2005

Link zum Volltext

Verfügbarkeit prüfen

Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis

Journal of drugs in dermatology, 2011-04, Vol.10 (4), p.366

Bagel, Jerry

2011

Link zum Volltext

Verfügbarkeit prüfen

Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis

Journal of drugs in dermatology, 2023-08, Vol.22 (8), p.766

2023

Link zum Volltext

Verfügbarkeit prüfen

A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy

Journal of drugs in dermatology, 2018-08, Vol.17 (8), p.845

2018

Link zum Volltext

Verfügbarkeit prüfen

Bimekizumab versus Adalimumab in Plaque Psoriasis

The New England journal of medicine, 2021-07, Vol.385 (2), p.130-141

2021

Link zum Volltext

Verfügbarkeit prüfen

Biosimilars

Journal of drugs in dermatology, 2014-07, Vol.13 (7), p.788

Bagel, Jerry

2014

Link zum Volltext

Verfügbarkeit prüfen

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

The New England journal of medicine, 2015-10, Vol.373 (14), p.1318-1328

2015

Link zum Volltext

Verfügbarkeit prüfen

27611 Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)

Journal of the American Academy of Dermatology, 2021-09, Vol.85 (3), p.AB156-AB156

2021

Link zum Volltext

Verfügbarkeit prüfen

Immunogenicity and skin clearance recapture in clinical studies of brodalumab

Journal of the American Academy of Dermatology, 2020-02, Vol.82 (2), p.344-351

2020

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 137

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(125)
Mit Volltextzugriff
(96)

Publikationsform

Artikel
(134)
Buchkapitel
(3)

Sprache

Englisch
(137)
Japanisch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(70)
Life Sciences & Biomedicine
(69)
Dermatology
(68)
Humans
(65)
Psoriasis - Drug Therapy
(45)
Psoriasis
(36)
Female
(34)
Severity Of Illness Index
(33)
Treatment Outcome
(33)
Male
(30)
Middle Aged
(29)
Adult
(27)
Biological And Medical Sciences
(18)
Double-Blind Method
(17)
Medical Sciences
(17)
Psoriasis - Pathology
(17)
Dermatologic Agents - Therapeutic Use
(14)
Quality Of Life
(14)
Dermatologic Agents - Administration & Dosage
(13)
Psoriasis. Parapsoriasis. Lichen
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Serlopitant for psoriatic pruritus: A phase 2 randomized, double-blind, placebo-controlled clinical trial

A review of phototherapy protocols for psoriasis treatment

From the Medical Board of the National Psoriasis Foundation: The risk of cardiovascular disease in individuals with psoriasis and the potential impact of current therapies

Impact of psoriasis disease severity and special area involvement on patient-reported outcomes in the real world: an analysis from the CorEvitas psoriasis registry

Treatment strategies, management of comorbidities, and the role of IL-23 inhibitors in moderate to severe psoriasis

Adjunctive Use of Calcipotriene/Betamethasone Dipropionate Foam in a Real-World Setting Curtails the Cost of Biologics Without Reducing Efficacy in Psoriasis

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study

Moderate to severe plaque psoriasis with scalp involvement: A randomized, double-blind, placebo-controlled study of etanercept

Secukinumab is Superior to Ustekinumab in Clearing Skin in Patients with Moderate to Severe Plaque Psoriasis (16-Week CLARITY Results)

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis

Enthesitis and Dactylitis in Psoriatic Disease: A Guide for Dermatologists

Treat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy

Adjunctive Use of Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Patients With Psoriasis Treated With Ixekizumab

Treatment of intertriginous psoriasis: From the Medical Board of the National Psoriasis Foundation

34313 Improvement in disease severity and quality of life in patients with atopic dermatitis (AD) treated with dupilumab for up to 18 months: Real-world evidence from the PROSE registry

From the Medical Board of the National Psoriasis Foundation: Monitoring and vaccinations in patients treated with biologics for psoriasis

Decision points for the initiation of systemic treatment for psoriasis

Adalimumab plus narrowband ultraviolet B light phototherapy for the treatment of moderate to severe psoriasis

Tildrakizumab in Combination With Topical Halcinonide 0.1% Ointment for Treating Moderate to Severe Plaque Psoriasis

A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy

Bimekizumab versus Adalimumab in Plaque Psoriasis

Biosimilars

Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis

27611 Fixed-combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion for the treatment of plaque psoriasis in patients with 3-5% body surface area (BSA) and poor quality of life (QoL)

Immunogenicity and skin clearance recapture in clinical studies of brodalumab

Suchergebnisse filtern